Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METalmark: Amivantamab + Capmatinib in metastatic NSCLC
jRCT2041230093Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of amivantamab and capmatinib in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with adverse events by severity (Phase 1), Number of participants with dose-limiting toxicities (DLTs) and 1 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
amivantamabcapmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2041230093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230093.